FDA wants investigation into Avandia conflict: report
NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.
David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.
Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.
- Tweet this
- Share this
- Digg this
Some countries are yet to shoulder their share of the Ebola response burden and some restrictions on aid workers returning home from West African nations hit hardest by the disease could deter thousands from helping, Samantha Power, the U.S. envoy to the United Nations, said on Thursday. Full Article
'Disastrous' health campaign feeds Pakistan's worrying polio spike. Full Article